Prostatic Neoplasms
📧 Sign up to get email alerts when something new happens for Prostatic Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH
EU authorization of Docetaxel Kabi (docetaxel) for multiple cancer indications including head and neck neoplasms, non-small cell lung carcin…
-
EMA approval · 2026-08-05EMA Authorised: Degarelix Accord (degarelix acetate) — Accord Healthcare S.L.U.
Degarelix Accord (degarelix acetate) has been authorised by the EMA for prostatic neoplasms.
-
EMA approval · 2026-07-30EMA Authorised: Xofigo (radium (223Ra) dichloride) — Bayer AG
EMA authorises Xofigo (radium-223 dichloride) for therapeutic use in prostatic neoplasms.
-
EMA approval · 2026-07-29EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.
Xtandi (enzalutamide) has been authorised in the EU for prostatic neoplasms by Astellas Pharma Europe B.V.
-
EMA approval · 2026-07-02EMA Authorised: Xtandi (enzalutamide) — Astellas Pharma Europe B.V.
Authorisation granted for Xtandi (enzalutamide) by EMA for prostatic neoplasms.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer [Phase 3]
Phase 3 trial assessing adding apalutamide to radiotherapy and LHRH agonist in high-risk hormone-sensitive prostate cancer patients.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
This ClinicalTrials.gov entry describes imaging studies used to assess the local response of prostate cancer to radiation therapy in an ongo…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) [Phase 1]
This trial update reports the completion of a Phase 1 study of Opevesostat (MK-5684) in Chinese participants with metastatic castration-resi…
-
EMA approval · 2026-02-24EMA Authorised: Enzalutamide Viatris (enzalutamide) — Viatris Limited
EMA authorised a generic version of enzalutamide (Enzalutamide Viatris) for prostatic neoplasms, with Viatris Limited as the marketing autho…
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC [Phase 2]
Phase 2 clinical trial update comparing 177Lu-PSMA therapy alone versus 177Lu-PSMA with ipilimumab and nivolumab in men with metastatic cast…
-
EMA approval · 2023-11-08EMA Authorised: Degarelix Accord (degarelix acetate) — Accord Healthcare S.L.U.
The EMA has authorised Degarelix Accord (degarelix acetate) for prostatic neoplasms, marking an approved drug in Europe.
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) [Phase 1]
Phase 1 study of escalating doses of a vaccine-based immunotherapy regimen for prostate cancer (PrCa VBIR) was terminated; results posted.
-
EMA approval · 2022-12-07EMA Authorised: Tookad (padeliporfin di-potassium) — STEBA Biotech S.A
The EMA has authorised Tookad (padeliporfin di-potassium) for prostatic neoplasms, with STEBA Biotech S.A. as the marketing authorization ho…
-
CLINICAL_TRIALS trial_result · 2022-10-07Clinical Trial Update: Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide [Phase 1, Phase 2]
Phase 1/Phase 2 trial update for Combidex USPIO in uterine and cervical neoplasms, completed.
-
EMA approval · 2022-10-04EMA Authorised: Firmagon (degarelix) — Ferring Pharmaceuticals A/S
EMA authorisation of Firmagon (degarelix) for prostatic neoplasms.
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
CLINICAL_TRIALS trial_result · 2022-05-11Clinical Trial Update: 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer [Phase 2, Phase 3]
Clinical trial update for 18F-DCFPyL PET/CT in men with prostate cancer, spanning Phase 2 and Phase 3, currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Stereotactic Radiotherapy for Oligometastatic Prostate Cancer [Phase 1, Phase 2]
Clinical trial update for stereotactic radiotherapy in oligometastatic prostate cancer (Phase 1/Phase 2) with unclear status.
-
CLINICAL_TRIALS trial_result · 2022-02-01Clinical Trial Update: MR Image Guided Therapy in Prostate Cancer [Phase 2]
Phase 2 clinical trial update on MR image-guided therapy for prostate cancer has completed with posted results.
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer [Phase 2]
Phase 2 trial assessing neoadjuvant PROSTVAC-VF with or without ipilimumab in prostate cancer was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-06Clinical Trial Update: Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients [Phase 4]
Phase 4 clinical trial update exploring low-dose neuroleptanalgesia for postoperative delirium in elderly patients; current status is unknow…
-
CLINICAL_TRIALS research · 2020-12-22Clinical Trial Update: Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines [Phase 1]
Phase 1 trial evaluating a multi-targeted recombinant vaccine (Ad5 PSA/MUC1/Brachyury) for castration-resistant prostate cancer; completed w…
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer [Phase 2]
Phase 2 trial evaluating dendritic cell-based vaccines loaded with allogeneic prostate cell lines in combination with androgen ablation for …
-
CLINICAL_TRIALS trial_result · 2020-05-04Clinical Trial Update: Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer [Phase 3]
Phase 3 trial update assessing safety, efficacy, and pharmacokinetics of leuprolide mesylate (LMIS 25 mg) in subjects with prostate cancer; …